Ontology highlight
ABSTRACT:
SUBMITTER: Suzuki N
PROVIDER: S-EPMC5276830 | biostudies-other | 2017 Jan
REPOSITORIES: biostudies-other
Suzuki Nobuaki N Hazama Shoichi S Iguchi Haruo H Uesugi Kazuhiro K Tanaka Hiroaki H Hirakawa Kosei K Aruga Atsushi A Hatori Takashi T Ishizaki Hidenobu H Umeda Yuzo Y Fujiwara Toshiyoshi T Ikemoto Tetsuya T Shimada Mitsuo M Yoshimatsu Kazuhiko K Shimizu Ryoichi R Hayashi Hiroto H Sakata Koichiro K Takenouchi Hiroko H Matsui Hiroto H Shindo Yoshitaro Y Iida Michihisa M Koki Yasunobu Y Arima Hideki H Furukawa Hiroyuki H Ueno Tomio T Yoshino Shigefumi S Nakamura Yusuke Y Oka Masaaki M Nagano Hiroaki H
Cancer science 20161219 1
We previously conducted a phase I clinical trial combining the HLA-A*2402-restricted KIF20A-derived peptide vaccine with gemcitabine for advanced pancreatic cancer (PC) and confirmed its safety and immunogenicity in cancer patients. In this study, we conducted a multicenter, single-armed, phase II trial using two antiangiogenic cancer vaccines targeting VEGFR1 and VEGFR2 in addition to the KIF20A peptide. We attempted to evaluate the clinical benefit of the cancer vaccination in combination with ...[more]